The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis

Womens Health (Lond). 2015 Nov;11(6):815-24. doi: 10.2217/whe.15.64. Epub 2015 Nov 30.

Abstract

Minivelle(®) (Noven Therapeutics, LLC, FL, USA) is an estradiol transdermal delivery system that has recently been approved in the USA for prevention of postmenopausal osteoporosis. The decline in estrogen during menopause leads to bone resorption, increasing the risk of fractures. Transdermal estradiol has been shown to increase bone mineral density. Safety studies of transdermal estradiol have shown a decreased risk in cardiovascular disease as compared with oral estrogen therapy. Minivelle is currently the smallest available transdermal estradiol patch, providing the lowest effective dose of estrogen.

Keywords: hormone therapy; menopause; osteoporosis prevention; transdermal estradiol.

Publication types

  • Review

MeSH terms

  • Bone Density / drug effects*
  • Estradiol / administration & dosage*
  • Estradiol / adverse effects
  • Estrogen Replacement Therapy / adverse effects
  • Estrogen Replacement Therapy / methods*
  • Female
  • Humans
  • Osteoporosis, Postmenopausal / prevention & control*
  • Transdermal Patch*

Substances

  • Estradiol